Abstract
Background: Understanding the complexities associated with the ischemic condition and identifying therapeutic targets in ischemia is a continued challenge in stroke biology. Emerging evidence reveals the potential involvement of epigenetic mechanisms in the incident and outcome of stroke, suggesting novel therapeutic options of targeting different molecules related to epigenetic regulation.
Objective: This review summarizes our current understanding of ischemic pathophysiology, describes various in vivo and in vitro models of ischemia, and examines epigenetic modifications associated with the ischemic condition. Method: We focus on microRNAs, DNA methylation, and histone modifying enzymes, and present how epigenetic studies are revealing novel drug target candidates in stroke. Conclusion: Finally, we discuss emerging approaches for the prevention and treatment of stroke and post-stroke effects using pharmacological interventions with a wide therapeutic window.Keywords: HDAC inhibitors, JMJD2 inhibitors, micro RNA, stroke, neurogenesis, angiogenesis, REST complex.
Graphical Abstract
Current Neuropharmacology
Title:Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Volume: 15 Issue: 6
Author(s): Priya Jhelum, Bhanu C. Karisetty, Arvind Kumar and Sumana Chakravarty*
Affiliation:
- Chemical Biology, CSIR-Indian Institute of Chemical Technology (IICT), Tarnaka, Hyderabad-500007,India
Keywords: HDAC inhibitors, JMJD2 inhibitors, micro RNA, stroke, neurogenesis, angiogenesis, REST complex.
Abstract: Background: Understanding the complexities associated with the ischemic condition and identifying therapeutic targets in ischemia is a continued challenge in stroke biology. Emerging evidence reveals the potential involvement of epigenetic mechanisms in the incident and outcome of stroke, suggesting novel therapeutic options of targeting different molecules related to epigenetic regulation.
Objective: This review summarizes our current understanding of ischemic pathophysiology, describes various in vivo and in vitro models of ischemia, and examines epigenetic modifications associated with the ischemic condition. Method: We focus on microRNAs, DNA methylation, and histone modifying enzymes, and present how epigenetic studies are revealing novel drug target candidates in stroke. Conclusion: Finally, we discuss emerging approaches for the prevention and treatment of stroke and post-stroke effects using pharmacological interventions with a wide therapeutic window.Export Options
About this article
Cite this article as:
Jhelum Priya, Karisetty C. Bhanu, Kumar Arvind and Chakravarty Sumana*, Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models, Current Neuropharmacology 2017; 15 (6) . https://dx.doi.org/10.2174/1570159X14666161213143907
DOI https://dx.doi.org/10.2174/1570159X14666161213143907 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Regulation of Inflammation and Myocardial Fibrosis in Experimental Autoimmune Myocarditis
Inflammation & Allergy - Drug Targets (Discontinued) Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design